Lessons learned from checkpoint blockade targeting PD-1 in multiple myeloma Review
| Authors: | Lesokhin, A. M.; Bal, S.; Badros, A. Z. |
| Review Title: | Lessons learned from checkpoint blockade targeting PD-1 in multiple myeloma |
| Abstract: | Immune checkpoints and agonists modulate ongoing, antigen-specific immune responses. Therapeutic blockade of CTLA-4, PD-1, and PD-L1 has proven to be an effective treatment approach for a subset of patients with a variety of cancers of epithelial, mesenchymal, or hematologic origin. In multiple myeloma, a B-cell lymphoid malignancy of terminally differentiated plasma cells, PD-1 pathway blockade is ineffective as a single agent. The initial promise in combination approaches utilizing anti–PD-1 with the immunomodulatory drugs, lenalidomide or pomalidomide, was not confirmed in randomized trials. Here, we explore available data for and against manipulation of the PD-1 pathway and other immune checkpoints in myeloma and highlight several promising concepts and challenges that face ongoing development of immunotherapeutics for this disease. © 2019 American Association for Cancer Research. |
| Journal Title: | Cancer Immunology Research |
| Volume: | 7 |
| Issue: | 8 |
| ISSN: | 2326-6066 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2019-08-01 |
| Start Page: | 1224 |
| End Page: | 1229 |
| Language: | English |
| DOI: | 10.1158/2326-6066.Cir-19-0148 |
| PUBMED: | 31371317 |
| PROVIDER: | scopus |
| PMCID: | PMC6891823 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work